ClinicalTrials.gg
CompletedNCT01493414JUMPUpdated Apr 26, 2019Results posted

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

A Phase 3 interventional study of INC424 in Myelofibrosis, sponsored by Novartis Pharmaceuticals. Completed at 273 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,233
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
Largest of 50
2,233 · median 45
Started
2011
with 5 others
Phase 3
6 of 50
none open now
Registered
11th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one has the largest enrollment, is one of 6 that started in 2011, is one of 6 in phase 3, and was the 11th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.

03

Conditions studied

  • Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Primary myelofibrosis
  • PMF
  • Post polycythemia myelofibrosis
  • PPV MF
  • Post-essential thrombocythemia myelofibrosis
  • PET-MF
  • INC424
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Patients must not be eligible for another ongoing INC424 clinical trial.
  2. Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised International Standard Criteria, irrespective of JAK2 mutation status..
  3. Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen (assessment to occur at the Screening Visit).

    The prognostic factors, defined by the International Working Group are:

    • Age > 65 years;
    • Presence of constitutional symptoms (weight loss, fever, night sweats);
    • Marked anemia ( \< 10g/dL)*;
    • Leukocytosis (history of white blood cell (WBC) > 25 x109/L);
    • Circulating blasts > 1%. * A hemoglobin value \< 10 g/dL must be demonstrated during the Screening Visit for patients who are not transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be considered to have hemoglobin \< 10 g/dL for the purpose of evaluation of risk factors.
  4. Patients with Intermediate-1 disease and splenomegaly must have a palpable spleen measuring 5 cm or greater from the costal margin to the point of greatest splenic protrusion.
  5. Patients must have a peripheral blood blast count of \< 10%.
  6. Patients with an (ECOG) performance status of 0, 1, or 2.
  7. Fedratinib pretreated patients with documented complete physical examination including full neurologic examination and cardiology assessment, thiamine level testing, and MRI of the brain if indicated based on signs or symptoms. Patients pretreated with fedratinib should have completed or be receiving thiamine supplementation according to the investigator's instructions.

Main Exclusion Criteria:

  1. Patients eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
  2. Patients with history of in past 3 years except for treated, early-stage squamous or basal cell carcinoma in situ.
  3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral INC424 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
  4. Patients with cardiac disease which in the Investigator's opinion may jeopardize the safety of the patient or the compliance with the protocol.
  5. Patients with currently uncontrolled or unstable angina, rapid or paroxysmal atrial fibrillation or recent (approximately 6 months) myocardial infarction or acute coronary syndrome.
  6. Patients with bacterial, fungal, parasitic or viral infection which require therapy. Patients with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
  7. Patients with known active hepatitis A, B, C or who are -positive.
  8. Patients with inadequate bone marrow reserve at the Baseline visit as demonstrated by:

    • (ANC) ≤ 1000/µL.
    • count \< 50,000/µL without the assistance of growth factors, thrombopoietic factors or platelet transfusions.
  9. Patients with any history of platelet counts \< 50,000/µL or ANC \< 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason.
  10. In the case of ruxolitinib pretreated patients, ruxolitinib primary resistant patients defined as:

    • No spleen reduction within the first 12 weeks after front line therapy with ruxolitinib.

    AND

    • No reduction in symptoms within the first 12 weeks after treatment with ruxolitinib.
  11. In the case of ruxolitinib pretreated patients, patients discontinuing ruxolitinib due to a Grade 4 Adverse event (AE) related or suspected to be related to ruxolitinib.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,233 participants (actual)

Study arms

  • Experimental
    INC424

    5 - 25 mg twice a day (BID)

    Drug: INC424

Interventions

  • DrugINC424

    All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.

    Also known as: Ruxolitinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years

    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.

    Time frame: Baseline up to approximately 5 years

Secondary outcomes

  1. Percentage of Participants With at Least 50% Reduction in Spleen Length

    Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).

    Time frame: Baseline up to approximately 5 years

  2. Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length

    Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length. Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.

    Time frame: Baseline up to approximately 5 years

  3. Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years

    ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.

    Time frame: Baseline up to approximately 5 years

  4. Change in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48

    The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.

    Time frame: Baseline and Week 48

  5. Time to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status

    Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.

    Time frame: Baseline up to approximately 5 years

  6. Medical Resource Utilization up to 5 Years

    Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.

    Time frame: Baseline up to approximately 5 years.

07

Results

Posted Apr 26, 2019

Participant flow

This was an expanded access study intended to provide an access path to ruxolitinib for patients with Myelofibrosis (MF) and to allow for collection of additional safety and efficacy data for ruxolitinib.

Participant flow — Overall Study
MilestoneINC424
Started2233
Completed1283
Not completed950
Withdrew: Adverse event405
Withdrew: Disease progression204
Withdrew: Death101
Withdrew: Physician decision93
Withdrew: Withdrawal by subject79
Withdrew: Protocol deviation27
Withdrew: Administrative problems25
Withdrew: Lost to follow-up16

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years

An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.

Time frame:
Baseline up to approximately 5 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years
ParticipantsINC424
Adverse Events2153
Serious adverse events830
SecondaryPercentage of Participants With at Least 50% Reduction in Spleen Length

Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).

Time frame:
Baseline up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction in Spleen Length
percentage of participantsINC424
Percentage of Participants With at Least 50% Reduction in Spleen Length71.7 (69.7 to 73.7)
SecondaryNumber of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length

Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length. Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.

Time frame:
Baseline up to approximately 5 years
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length
ParticipantsINC424 - RespondersINC424 - Stable DiseaseINC424 - Progressive DiseaseINC424 - Missing
Spleen length at baseline-Less than 5 cmNANANANA
Spleen length at baseline-Between 5 and 10 cm42133419
Spleen length at baseline-More than 10 cm742463019
SecondaryChange in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years

ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.

Time frame:
Baseline up to approximately 5 years
Reported as:
Count of participants · Participants
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years
ParticipantsINC424
Baseline - Grade 0 — Worst value post-baseline: Grade 0598
Baseline - Grade 0 — Worst value post-baseline: Grade 1377
Baseline - Grade 0 — Worst value post-baseline: Grade 262
Baseline - Grade 0 — Worst value post-baseline: Grade 312
Baseline - Grade 0 — Worst value post-baseline: Grade 47
Baseline - Grade 0 — Worst value post-baseline: Grade 50
Baseline - Grade 0 — Worst value post-baseline: Missing5
Baseline - Grade 1 — Worst value post-baseline: Grade 089
Baseline - Grade 1 — Worst value post-baseline: Grade 1629
Baseline - Grade 1 — Worst value post-baseline: Grade 2187
Baseline - Grade 1 — Worst value post-baseline: Grade 326
Baseline - Grade 1 — Worst value post-baseline: Grade 412
Baseline - Grade 1 — Worst value post-baseline: Grade 51
Baseline - Grade 1 — Worst value post-baseline: Missing16
Baseline - Grade 2 — Worst value post-baseline: Grade 03
Baseline - Grade 2 — Worst value post-baseline: Grade 143
Baseline - Grade 2 — Worst value post-baseline: Grade 2111
Baseline - Grade 2 — Worst value post-baseline: Grade 320
Baseline - Grade 2 — Worst value post-baseline: Grade 412
Baseline - Grade 2 — Worst value post-baseline: Grade 51
Baseline - Grade 2 — Worst value post-baseline: Missing7
Baseline - Grade 3 — Worst value post-baseline: Grade 00
Baseline - Grade 3 — Worst value post-baseline: Grade 10
Baseline - Grade 3 — Worst value post-baseline: Grade 20
Baseline - Grade 3 — Worst value post-baseline: Grade 31
Baseline - Grade 3 — Worst value post-baseline: Grade 40
Baseline - Grade 3 — Worst value post-baseline: Grade 50
Baseline - Grade 3 — Worst value post-baseline: Missing0
Baseline - Grade 4 — Worst value post-baseline: Grade 00
Baseline - Grade 4 — Worst value post-baseline: Grade 10
Baseline - Grade 4 — Worst value post-baseline: Grade 20
Baseline - Grade 4 — Worst value post-baseline: Grade 30
Baseline - Grade 4 — Worst value post-baseline: Grade 40
Baseline - Grade 4 — Worst value post-baseline: Grade 50
Baseline - Grade 4 — Worst value post-baseline: Missing0
Baseline - Missing — Worst value post-baseline: Grade 01
Baseline - Missing — Worst value post-baseline: Grade 18
Baseline - Missing — Worst value post-baseline: Grade 24
Baseline - Missing — Worst value post-baseline: Grade 31
Baseline - Missing — Worst value post-baseline: Grade 40
Baseline - Missing — Worst value post-baseline: Grade 50
Baseline - Missing — Worst value post-baseline: Missing0
SecondaryChange in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48

The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.

Time frame:
Baseline and Week 48
Reported as:
Mean · scores on a scale
Change in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48
scores on a scaleINC424
FACT-Lymphoma Baseline42.3 ± 10.20
FACT-Lymphoma Week 4847.9 ± 8.47
FACT-Lymphoma TOI Baseline77.9 ± 18.99
FACT-Lymphoma TOI Week 4886.8 ± 16.42
FACT-Lymphoma total score Baseline113.9 ± 24.01
FACT-Lymphoma total score Week 48123.3 ± 22.34
FACT-G Baseline71.6 ± 15.98
FACT-G Week 4875.5 ± 15.59
SecondaryTime to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status

Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.

Time frame:
Baseline up to approximately 5 years
Reported as:
Median · weeks
Time to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status
weeksINC424
FACT-Lym Total score median time to improvement10.9 (5.1 to 11.6)
FACIT - Fatigue score median time to improvement4.6 (4.4 to 4.6)
ECOG score median time to improvement63.1 (61.1 to 65.0)
SecondaryMedical Resource Utilization up to 5 Years

Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.

Time frame:
Baseline up to approximately 5 years.
Reported as:
Count of participants · Participants
Medical Resource Utilization up to 5 Years
ParticipantsINC424
Baseline- Dependency — End of Study - Dependency129
Baseline- Dependency — End of Study - Independency29
Baseline- Independency — End of Study - Dependency480
Baseline- Independency — End of Study - Independency1595

Adverse events

Collected over Adverse Events (AEs) were collected up to 24-months after last patient first visit (LPFV), approximately 5 years .. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INC424205/2,233 (9.2%)830/2,233 (37.2%)2,008/2,233 (89.9%)
Most frequent serious events
Showing 10 of 565
Most frequent serious events
EventINC424
PneumoniaInfections and infestations123/2233
AnaemiaBlood and lymphatic system disorders94/2233
PyrexiaGeneral disorders79/2233
Cardiac failureCardiac disorders43/2233
DyspnoeaRespiratory, thoracic and mediastinal disorders36/2233
SepsisInfections and infestations31/2233
Abdominal painGastrointestinal disorders28/2233
Respiratory failureRespiratory, thoracic and mediastinal disorders26/2233
ThrombocytopeniaBlood and lymphatic system disorders24/2233
Urinary tract infectionInfections and infestations23/2233
Most frequent other events
Showing 10 of 24
Most frequent other events
EventINC424
AnaemiaBlood and lymphatic system disorders1300/2233
ThrombocytopeniaBlood and lymphatic system disorders990/2233
AstheniaGeneral disorders331/2233
PyrexiaGeneral disorders310/2233
DiarrhoeaGastrointestinal disorders267/2233
FatigueGeneral disorders215/2233
Platelet count decreasedInvestigations198/2233
HeadacheNervous system disorders191/2233
CoughRespiratory, thoracic and mediastinal disorders186/2233
Oedema peripheralGeneral disorders182/2233

Baseline characteristics

Age, Continuous
Age, Continuous(years)INC424
Mean65.6 ± 10.50
Sex: Female, Male
Sex: Female, Male(Participants)INC424
Female1016
Male1217
Race (NIH/OMB)
Race (NIH/OMB)(Participants)INC424
American Indian or Alaska Native6
Asian23
Native Hawaiian or Other Pacific Islander1
Black or African American20
White2087
More than one race96
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)INC424
Hispanic/Latino509
Chinese1
Indian (Indian subcontinent)1
Japanese0
Mixed Ethnicity15
Others1707
ECOG score
ECOG score(Participants)INC424
01061
1960
2197
31
40
Missing14
08

Study locations

273 sites
  • Novartis Investigative Site
    Alger, Algeria
  • Novartis Investigative Site
    Caba, Buenos Aires 1209, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    Paraná, Entre Rios E3100BBJ, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1114AAN, Argentina
  • Novartis Investigative Site
    Cordoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Corrientes, W3410AVV, Argentina
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Linz, A-4010, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Wien, 1140, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Arlon, Luxembourg 1210, Belgium
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Hasselt, 3500, Belgium
  • Novartis Investigative Site
    Kortrijk, 8500, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Roeselare, 8800, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Goiania, GO 74605-050, Brazil
  • Novartis Investigative Site
    Belo Horizonte, MG 30130-100, Brazil
  • Novartis Investigative Site
    Curitiba, PR 80060-900, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20.211-030, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90035-003, Brazil
  • Novartis Investigative Site
    Campinas, SP 13083-970, Brazil
  • Novartis Investigative Site
    Ribeirao Preto, SP 14048-900, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01224-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 05651-901, Brazil
  • Novartis Investigative Site
    São Paulo, SP 08270-070, Brazil
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V6Z1Y6, Canada
  • Novartis Investigative Site
    Moncton, New Brunswick E1C 6Z8, Canada
  • Novartis Investigative Site
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Windsor, Ontario N8W 2X3, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2W 1S6, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Novartis Investigative Site
    Bogota, Cundinamarca 111411, Colombia
  • Novartis Investigative Site
    Medellín, Colombia
  • Novartis Investigative Site
    Brno, Czech Republic 639 00, Czechia
  • Novartis Investigative Site
    Hradec Kralove, Czech Republic 500 05, Czechia
  • Novartis Investigative Site
    Praha 2, Czech Republic 128 20, Czechia
  • Novartis Investigative Site
    Olomouc, 775 20, Czechia
  • Novartis Investigative Site
    Mannheim, Baden-Württemberg 68305, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 14195, Germany
  • Novartis Investigative Site
    Bochum, 44787, Germany
  • Novartis Investigative Site
    Bonn, 53113, Germany
  • Novartis Investigative Site
    Bonn, 53119, Germany
  • Novartis Investigative Site
    Bottrop, 46236, Germany
  • Novartis Investigative Site
    Bremen, 28177, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Darmstadt, 64283, Germany
  • Novartis Investigative Site
    Dortmund, 44263, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duisburg, 47166, Germany
  • Novartis Investigative Site
    Düsseldorf, 40225, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, Oder, 15236, Germany
  • Novartis Investigative Site
    Frankfurt, 60389, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Friedrichshafen, 88045, Germany
  • Novartis Investigative Site
    Goslar, 38642, Germany
  • Novartis Investigative Site
    Greifswald, 17475, Germany
  • Novartis Investigative Site
    Göttingen, D-37075, Germany
  • Novartis Investigative Site
    Halle, 06110, Germany
  • Novartis Investigative Site
    Hamburg, 20099, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamm, 59063, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Hildesheim, 31135, Germany
  • Novartis Investigative Site
    Ingolstadt, 85049, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kiel, D-24116, Germany
  • Novartis Investigative Site
    Koeln, 50671, Germany
  • Novartis Investigative Site
    Köln, 50937, Germany
  • Novartis Investigative Site
    Leer, 26789, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Marburg, 35037, Germany

Showing the first 100 of 273 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19. PubMed 33210570 ↗
  • Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, Garcia-Hernandez C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hanel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4. PubMed 32017044 ↗
  • Tavares R, Souza CA, Paley C, Bouard C, Tiwari R, Pasquini R. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort. Hematol Transfus Cell Ther. 2020 Jan-Mar;42(1):46-53. doi: 10.1016/j.htct.2019.01.009. Epub 2019 Apr 25. PubMed 31235325 ↗
  • Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677. Epub 2016 May 31. PubMed 27247324 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2011
First posted
Dec 16, 2011
Start
Aug 16, 2011
Primary completionActual
Jan 26, 2017
CompletionActual
Jan 26, 2017
Results first posted
Apr 26, 2019
Last update
Apr 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01493414
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Aug 16, 2011
Primary completion
Jan 26, 2017
Completion
Jan 26, 2017
Results posted
Apr 26, 2019
Last update
Apr 26, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion